New eye drops aim to soothe red eyes fast
NCT ID NCT07531043
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times
Summary
This Phase 3 trial tests an investigational eye drop (FID123472) containing apraclonidine to reduce redness in adults with minor eye irritation. About 230 participants will receive either the active drop or a placebo (vehicle). The main goals are to see if redness improves within 15 minutes and lasts up to 14 hours.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Apraclonidine ophthalmic solution (0.125%)
- What this could lead to
- If successful, this could provide a new prescription option for quickly and safely reducing eye redness from minor irritations.
- What could go wrong
- This is a Phase 3 trial, but it's testing a known drug in a new formulation. The effect may be modest or short-lived, and side effects like eye irritation or allergic reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 230 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form. * Willing and able to follow all instructions and attend all study visits. * History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion. * Baseline investigator-assessed ocular redness score of 0.5 or higher in at least one eye at Visit 1 when applicable and a score of greater than 1.0 in both eyes on a 5-point scale prior to randomization on Day 1 (Visit 2). * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Known contraindications or sensitivity to the use of any of the investigational product(s) or their components, or any other medication required by the protocol. * Ocular surgical intervention within 6 months prior to Visit 1 or during the study. * Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study specific parameters. * Use of any of the prohibited medications or devices as specified in the study protocol. * Out-of-range vital signs (blood pressure and/or pulse rate) as defined in the study protocol. * Abnormal intraocular pressure. * Other protocol-defined exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ocular hyperemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, 76134, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.